Challenges in the analytical method development and validation for an unstable active pharmaceutical ingredient. 2006

Peter Sajonz, and Yan Wu, and Theresa K Natishan, and Neil T McGachy, and David Detora
Merck Research Laboratories, Merck & Co., Inc., P.O. Box 2000, RY801-A101, Rahway, NJ 07065, USA.

A sensitive high-performance liquid chromatography (HPLC) impurity profile method for the antibiotic ertapenem is developed and subsequently validated. The method utilizes an Inertsil phenyl column at ambient temperature, gradient elution with aqueous sodium phosphate buffer at pH 8, and acetonitrile as the mobile phase. The linearity, method precision, method ruggedness, limit of quantitation, and limit of detection of the impurity profile HPLC method are found to be satisfactory. The method is determined to be specific, as judged by resolving ertapenem from in-process impurities in crude samples and degradation products that arise from solid state thermal and light stress, acid, base, and oxidative stressed solutions. In addition, evidence is obtained by photodiode array detection studies that no degradate or impurity having a different UV spectrum coeluted with the major component in stressed or unstressed samples. The challenges during the development and validation of the method are discussed. The difficulties of analyzing an unstable active pharmaceutical ingredient (API) are addressed. Several major impurities/degradates of the API have very different UV response factors from the API. These impurities/degradates are synthesized or prepared by controlled degradation and the relative response factors are determined.

UI MeSH Term Description Entries
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D000077727 Ertapenem A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery. Ertapenem Sodium,Invanoz,Invanz
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face
D047090 beta-Lactams Four-membered cyclic AMIDES, best known for the PENICILLINS based on a bicyclo-thiazolidine, as well as the CEPHALOSPORINS based on a bicyclo-thiazine, and including monocyclic MONOBACTAMS. The BETA-LACTAMASES hydrolyze the beta lactam ring, accounting for BETA-LACTAM RESISTANCE of infective bacteria. beta-Lactam,4-Thia-1-Azabicyclo(3.2.0)Heptanes,4-Thia-1-Azabicyclo(4.2.0)Octanes,beta Lactam,beta Lactams

Related Publications

Peter Sajonz, and Yan Wu, and Theresa K Natishan, and Neil T McGachy, and David Detora
February 2022, Journal of chromatographic science,
Peter Sajonz, and Yan Wu, and Theresa K Natishan, and Neil T McGachy, and David Detora
January 2014, Analytica chimica acta,
Peter Sajonz, and Yan Wu, and Theresa K Natishan, and Neil T McGachy, and David Detora
October 2017, Journal of pharmaceutical and biomedical analysis,
Peter Sajonz, and Yan Wu, and Theresa K Natishan, and Neil T McGachy, and David Detora
April 2024, AAPS PharmSciTech,
Peter Sajonz, and Yan Wu, and Theresa K Natishan, and Neil T McGachy, and David Detora
October 2017, Journal of pharmaceutical and biomedical analysis,
Peter Sajonz, and Yan Wu, and Theresa K Natishan, and Neil T McGachy, and David Detora
September 2005, Journal of pharmaceutical and biomedical analysis,
Peter Sajonz, and Yan Wu, and Theresa K Natishan, and Neil T McGachy, and David Detora
February 1998, International journal of cosmetic science,
Peter Sajonz, and Yan Wu, and Theresa K Natishan, and Neil T McGachy, and David Detora
March 2010, Bioanalysis,
Peter Sajonz, and Yan Wu, and Theresa K Natishan, and Neil T McGachy, and David Detora
July 2008, Journal of pharmaceutical and biomedical analysis,
Peter Sajonz, and Yan Wu, and Theresa K Natishan, and Neil T McGachy, and David Detora
July 2011, Pharmaceutical methods,
Copied contents to your clipboard!